320 related articles for article (PubMed ID: 35333600)
1. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
[TBL] [Abstract][Full Text] [Related]
2. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
3. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
5. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
[TBL] [Abstract][Full Text] [Related]
7. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J; Li H; Yan Z; Zhou D; Wang Y; Qi Y; Cao J; Li D; Cheng H; Sang W; Zhu F; Sun H; Chen W; Qi K; Yan D; Qiu T; Qiao J; Yao R; Liu Y; Wang X; Zhang Y; Peng S; Huang CH; Zheng J; Li Z; Chang AH; Xu K
J Clin Oncol; 2023 May; 41(14):2583-2593. PubMed ID: 36881785
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
9. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
11. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
Shi M; Wang J; Huang H; Liu D; Cheng H; Wang X; Chen W; Yan Z; Sang W; Qi K; Li D; Zhu F; Li Z; Qiao J; Wu Q; Zeng L; Fei X; Gu W; Miao Y; Xu K; Zheng J; Cao J
Nat Commun; 2024 Apr; 15(1):3371. PubMed ID: 38643278
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
[TBL] [Abstract][Full Text] [Related]
15. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
16. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
17. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M;
Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643
[TBL] [Abstract][Full Text] [Related]
18. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]